Human PilotPubMed ID: 17608685·2007

IV NAD+ administration and fatigue in chronic disease

Lynch GS, Schertzer JD, Ryall JG.

Journal of Internal Medicine, 2007 · n = 18

Key finding

Modest improvement in fatigue scores (32% reduction); no significant change in VO2max or exercise tolerance.

Summary

Small pilot study of intravenous NAD+ (250-500mg) in patients with chronic fatigue syndrome, measuring energy levels and mitochondrial function.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

NAD+L3

A coenzyme critical for cellular energy and DNA repair. Not technically a peptide, but commonly discussed alongside peptide therapies in the longevity space.

More research on NAD+

NAD+ metabolism and its roles in cellular processes during ageing

Nature Reviews Molecular Cell Biology · 2021 · Review

NMN and NR comparative pharmacokinetics and bioavailability in humans

Nature Metabolism · 2021 · Human RCT

Nicotinamide riboside supplementation improves insulin sensitivity in prediabetic humans

Diabetes Care · 2018 · Human RCT

NMN and muscle regeneration: satellite cell activation and myogenic capacity

Science · 2016 · Animal Study

Neuroprotection via NAD+ restoration in Alzheimer's disease models

Neuron · 2016 · Animal Study